VitroScan utilizes ex vivo 3D micro tumor assays to evaluate the efficacy of cancer treatments based on individual patient biomarker profiles. This predictive testing enables healthcare providers to select the most effective therapies, improving treatment outcomes and minimizing unnecessary interventions.
Funding
$2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Selecting the most effective cancer treatment for a patient is challenging due to the heterogeneity of tumors and individual patient responses. Traditional methods often lack the ability to predict treatment outcomes accurately, leading to ineffective therapies and unnecessary interventions.
Solution
VitroScan offers ex vivo 3D micro tumor assays that evaluate the efficacy of cancer treatments based on individual patient biomarker profiles. By creating a micro tumor model from a patient's biopsy, VitroScan can test various treatments and predict their effectiveness before administration. This predictive testing enables healthcare providers to make informed decisions, select the most effective therapies, and improve treatment outcomes. The assays provide reliable data to support clinical decision-making and minimize ineffective treatments.
Target Audience
VitroScan's primary customers are healthcare providers, oncologists, and pharmaceutical companies involved in cancer treatment and drug development.
Features
- Ex vivo 3D micro tumor assays using patient-derived tumor cells
- Evaluation of treatment efficacy based on individual patient biomarker profiles
- Predictive testing to identify the most effective therapies before administration
- Reliable data to support clinical decision-making